Onco Clinic Consult S.A.
- Address
- lock Available on a paid plan
Onco Clinic Consult S.A. - Advanced Oncology Research Center
Onco Clinic Consult S.A. is a specialized oncology research center with extensive expertise in evaluating novel therapeutic approaches for advanced and metastatic cancers. The center demonstrates particular strength in conducting complex Phase 2 and Phase 3 clinical trials, with a primary focus on immunotherapy combinations, targeted therapies, and next-generation antibody-drug conjugates across multiple solid tumor types.
- Non-small cell lung cancer (NSCLC) - first-line and advanced disease treatment with immune checkpoint inhibitors, biosimilars, and combination therapies
- Breast cancer - HER2-positive disease, hormone receptor-positive early and metastatic disease, and novel endocrine therapies
- Gastrointestinal malignancies - HER2-positive gastroesophageal adenocarcinoma and rare kidney cancer subtypes
- Head and neck squamous cell carcinoma - locally advanced unresected disease with immunotherapy approaches
The research center's portfolio reflects deep experience with pembrolizumab-based regimens and comparative effectiveness trials, positioning them at the forefront of precision oncology research. Their participation in pivotal registration trials evaluating antibody-drug conjugates such as datopotamab deruxtecan and trastuzumab deruxtecan, alongside innovative immunotherapy combinations with LAG-3 inhibitors and bispecific antibodies, demonstrates their commitment to advancing cutting-edge cancer treatments. The center also maintains expertise in evaluating selective estrogen receptor degraders (SERDs) and adjuvant endocrine therapy strategies for breast cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 50 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 50 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Daiichi Sankyo Inc.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onco Clinic Consult S.A.
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07) | Daiichi Sankyo Inc. | Phase III | Not Recruiting | Nov 2023 | — |
IMP list
lock Showing 1 of 50 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2020-05-05 | 2025-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.